News Release

Esophageal cancer risk higher in medically treated GERD patients with fewest symptoms

Peer-Reviewed Publication

University of Pittsburgh Schools of the Health Sciences

PITTSBURGH, July 18 – Medically treated patients with mild or no symptoms of gastroesophageal reflux disease (GERD) are at higher risk for developing esophageal cancer than those with severe GERD symptoms, according to a University of Pittsburgh study published in the current issue of Archives of Surgery.

Many patients who develop adenocarcinoma, a common form of esophageal cancer, are unaware that they have Barrett's esophagus – a change in the cells lining the esophagus often due to repeated stomach acid exposure. In some cases, Barrett's esophagus develops into esophageal cancer.

"Typically, patients with severe GERD symptoms are screened for Barrett's esophagus, but those with mild or absent symptoms are not. Unfortunately, many patients who develop adenocarcinoma don't know that they have Barrett's esophagus until it has transformed into cancer and become advanced, leading to obstruction," said principal investigator Blair A. Jobe, M.D., professor and director of esophageal research and esophageal diagnostics and therapeutic endoscopy, Department of Cardiothoracic Surgery, Pitt School of Medicine.

The study included 769 GERD patients who presented for their first upper endoscopy, in which a flexible endoscopic camera is guided through the esophagus and stomach to look for tissue changes. Participants were separated into three groups: patients who were referred for upper endoscopy for any clinical indication regardless of symptoms; patients with typical GERD symptoms, such as heartburn, regurgitation and difficulty swallowing; and patients with atypical GERD symptoms, such as hoarseness, throat-clearing, mucus, coughing and a lump sensation in the throat.

All study participants underwent endoscopy and completed questionnaires and a detailed medication history. Endoscopy revealed that 122 of these patients, or 15.9 percent, had Barrett's esophagus or adenocarcinoma. Patients who were adequately managing their GERD symptoms with proton pump inhibitors (PPIs) were 61 percent more likely to have Barrett's esophagus or adenocarcinoma if they reported no severe GERD symptoms, compared to patients taking PPIs who reported severe symptoms. Patients with severe GERD symptoms often experienced irritation or swelling of the esophagus, but that was associated with decreased odds of having esophageal cancer.

"Our research indicates that even patients without severe symptoms may benefit from Barrett's esophagus screening," Dr. Jobe noted. "If GERD patients are screened early enough, there is a better chance that Barrett's esophagus can be identified before it becomes cancerous," he stated. "We are learning that the chronic and long-term use of PPIs may not be entirely without consequences and may lead to more insidious problems such as calcium malabsorption or cause one to be asymptomatic in the face of continued esophageal injury from GERD."

Dr. Jobe and his Pitt colleagues have established the Barrett's Esophagus Risk Consortium (BERC), in which primary care patients are being screened with in-office, small-caliber, unsedated endoscopy in an attempt to better understand risk factors for the condition as well as lower the threshold for screening. The multicenter effort is funded by the National Institutes of Health.

###

Study co-authors include Katie S. Nason, M.D., M.P.H., Omar Awais, M.D., Matthew J. Schuchert, M.D., and James D. Luketich, M.D., all from Pitt; and Promporn Paula Wichienkuer, M.D., M.P.H., Robert W. O'Rourke, M.D., John G. Hunter, M.D., and Cynthia D. Morris, Ph.D., M.P.H., all from Oregon Health and Science University.

The study was funded by the Robert Anthony McHugh Research Fund for the Prevention and Early Detection of Esophageal Cancer, David Gold and Irene Blumenkrantz Esophageal Cancer Research Fund, the Sampson Family Endowed Chair, the UPMC Heart, Lung and Esophageal Surgery Institute, the American Surgical Association Foundation Fellowship Award and grants from the National Institutes of Health.

About the University of Pittsburgh School of Medicine

As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1997.

Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see www.medschool.pitt.edu.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.